BMEA vs. XERS, MAZE, TECX, MGTX, MLYS, TRDA, RNAC, HUMA, ARCT, and SNDL
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Xeris Biopharma (XERS), Maze Therapeutics (MAZE), Tectonic Therapeutic (TECX), MeiraGTx (MGTX), Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), Cartesian Therapeutics (RNAC), Humacyte (HUMA), Arcturus Therapeutics (ARCT), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.
Biomea Fusion vs.
Xeris Biopharma (NASDAQ:XERS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment.
Biomea Fusion has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Biomea Fusion's return on equity.
Xeris Biopharma presently has a consensus target price of $5.15, suggesting a potential upside of 37.33%. Biomea Fusion has a consensus target price of $39.36, suggesting a potential upside of 1,037.68%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Xeris Biopharma.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 27.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Xeris Biopharma has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500.
In the previous week, Xeris Biopharma had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Xeris Biopharma and 1 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.93 beat Xeris Biopharma's score of 0.65 indicating that Biomea Fusion is being referred to more favorably in the news media.
Xeris Biopharma has higher revenue and earnings than Biomea Fusion. Xeris Biopharma is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma received 86 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 69.90% of users gave Xeris Biopharma an outperform vote while only 69.05% of users gave Biomea Fusion an outperform vote.
Summary
Xeris Biopharma and Biomea Fusion tied by winning 9 of the 18 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
This page (NASDAQ:BMEA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BMEA Stock Alerts